CVS Caremark today announced a global settlement with the Federal Trade Commission (FTC) which further advances the company's leadership in delivering greater affordability for prescription drugs. The settlement resolves all outstanding FTC litigation and investigations related to CVS Health® (NYSE:CVS) — including its pharmacy benefits management and affiliated pharmacy businesses — involving rebate, pharmacy network contracting, and vertical integration issues.